Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors
Hadi, Soha R Abd El; Soliman, Dalia H; Elrazaz, Eman; Khaled A M Abouzid; Lasheen, Deena S.;
Abstract
In our attempt to discover effective anticancer agents, three series of novel quinazoline-based compounds have been designed, synthesized and tested as VEGFR-2 inhibitors. Five quinazoline -2-carboxamide derivatives (5d, 5e, 5 h, 5i, 5j) revealed potent nanomolar VEGFR-2 inhibition with IC50 values of 12.1, 40.3, 15.5, 13.1 and 57.4 nM, respectively, superior to that of the reference drug sorafenib (IC50 78.9 nM). Additionally, the quinazoline 2-carboxylate derivative bearing a fluorine substituent in middle ring (7a) showed IC50 values of 14.8 nM. Most of the new synthesized compounds are examined on NCI sixty cell lines of human cancer cells. Furthermore, molecular modeling study was administered to realize any clarification of the binding mode in the inactive VEGFR-2 conformation that demonstrates compatible binding modes similar to those of sorafenib and regorafenib. Finally, several ADME descriptors were calculated through a predictive kinetic study.
Other data
Title | Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors | Authors | Hadi, Soha R Abd El; Soliman, Dalia H; Elrazaz, Eman ; Khaled A M Abouzid ; Lasheen, Deena S. | Keywords | ADME;VEGFR-2;Quinazoline;Inhibitory activity;Docking study | Issue Date | Aug-2020 | Publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | Journal | Bioorganic Chemistry | Volume | 101 | ISSN | 0045-2068 | DOI | 10.1016/j.bioorg.2020.103961 | PubMed ID | 32480170 | Scopus ID | 2-s2.0-85085313420 | Web of science ID | WOS:000552629800007 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.